

Lesotho Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Lesotho			
2. Grant number: 18-LSO-12d-X / 12-LSO-08a-Y / 18-LSO-25a-Y			
3. Date of Decision Letter: 10 April 2018			
4. Date of the Partnership Framework Agreement: 30 November 2012			
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 4 dose(s) per vial , LIQUID			
8. Programme duration¹: 2014 - 2018			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2014-2017	2018	Total ²
Programme Budget (US\$)	US\$1,526,568 ³	US\$ 338,000	US\$ 1,864,568
10. Vaccine introduction grant (in US\$) / Product Switch Grant :			
<ul style="list-style-type: none"> • US\$ 100,000 was disbursed on 1 October 2014 to support the introduction of PCV. • Lesotho is eligible for US\$30,000 Product Switch Grant. The country has requested US\$ 25,877 and therefore this amount will be disbursed to support with the costs of the product switch. 			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement ⁴)			
Type of supplies to be purchased with Gavi funds in each year	2014-2017	2018	
Number of Pneumococcal vaccines doses		100,400	
Annual Amounts (US\$)	US\$1,526,568 ⁵	US\$338,000	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable			

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

14. Co-financing obligations: Reference code: 18-LSO-12d-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2018
Number of vaccine doses	8,600
Number of AD syringes	8,400
Number of safety boxes	100
Value of vaccine doses (US\$)	US\$26,227
Total co-financing payments (US\$) (including freight)	US\$27,000

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements:


Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions

The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.

Signed by,



On behalf of Gavi

Hind Khatib-Othman
 Managing Director, Country Programmes
 10 April 2018